HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schulman, S. P. Articles by Gerstenblith, G. Search for Related Content PubMed PubMed Citation Articles by Schulman, S. P. Articles by Gerstenblith, G.

Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina

Steven P. Schulman, MD^*,*, David R. Thiemann, MD^*, Pamela Ouyang, MD, FACC^*, Nisha C. Chandra, MD^*, Douglas S. Schulman, MD, FACC, Steven E. Reis, MD, FACC, Michael Terrin, MD, Sandra Forman, MA, Cicero Piva de Albuquerque, MD^||, Raymond D. Bahr, MD, FACC^¶, Susan N. Townsend, BSN^*, Rosalie Cosgriff, RCT^* and Gary Gerstenblith, MD, FACC^*

^* Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Allegheny General Hospital, Pittsburgh, Pennsylvania USA
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
Maryland Medical Research Institute, Baltimore, Maryland, USA
^|| Unidade Coronariana-InCor, Sao Paulo, Brazil
^¶ St. Agnes Medical Center, Baltimore, Maryland USA

View larger version (19K): [in a new window]   Figure 1 The rates of in-hospital death, myocardial infarction (MI), emergency percutaneous intervention (PCI) and emergency coronary artery bypass surgery (CABG) are shown for patients randomized to each group. Patients underwent revascularization for recurrent ischemic symptoms or high-risk presentation. There were no differences in hospital events among the three randomized groups, p = 0.91. E = conjugated equine estrogen; MPA = medroxyprogesterone; PLBO = placebo.

View larger version (14K): [in a new window]   Figure 2 Six-month rates of death or nonfatal myocardial infarction among the three randomized groups. Event rates did not differ, p = 0.97. E = conjugated equine estrogen; MPA = medroxyprogesterone; PLBO = placebo.

View larger version (16K): [in a new window]   Figure 3 Six-month rates of death, nonfatal myocardial infarction or need for revascularization (coronary artery bypass surgery or percutaneous intervention) among the three randomized groups. Most of the events occurred early, and hormone therapy did not reduce the adverse event rate, p = 0.98. E = conjugated equine estrogen; MPA = medroxyprogesterone; PLBO = placebo.